ymjЯкутский медицинский журналYakut Medical Journal1813-19052312-1017ЯНЦ КМП10.25789/YMJ.2019.65.29ymj-863Research ArticleНАУЧНЫЕ ОБЗОРЫ И ЛЕКЦИИSCIENTIFIC REVIEWS AND LECTURESЛечение детей с остеосаркомойTreatment of children with osteosarcomaСенжаповаЭ. Р.SenzhapovaE. R.

Сенжапова Эльмира Рифатовна – к.м.н., н.с.

Sengapova Elmira, PhD, Scientific Researcher of the Research Institute of the Pediatric Oncology and Hematology

115478, Moscow, Kashirskoye sh., 24

https://orcid.org/0000-0002-8398-7001РыковМ. Ю.RykovM. Yu.

Рыков Максим Юрьевич – к.м.н., зам. Директора;

Доцент

гл. внештат. детский специалист онколог Минздрава России по центральному федеральному округу

Rykov Maxim, PhD, Deputy Director of the Scientific Researcher of the Research Institute of the Pediatric Oncology and Hematology;

associate professor of the Department of Oncology

the chief freelance children’s specialist oncologist of the Ministry of Health of Russia in the Central Federal District

115478, Moscow, Kashirskoye sh., 24

wordex2006@rambler.ruФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияN.N. Blockhin Medical Research Center of Oncology of the Ministry of Health of RussiaRussian FederationНИИ ДОГ ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России; ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияN.N. Blockhin Medical Research Center of Oncology of the Ministry of Health of Russia; First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)Russian Federation2019160820250194102Copyright © Сенжапова Э.Р., Рыков М.Ю., 20252025Сенжапова Э.Р., Рыков М.Ю.Senzhapova E.R., Rykov M.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ymj.elpub.ru/jour/article/view/863

В статье приведены статистические данные, описывающие заболеваемость остеосаркомой у детей, классификация остеосаркомы, описание основных локализаций, а также подробное описание существующих протоколов лечения, включая персонализированную терапию. Подробно описаны литературные данные – результаты лечения детей с остеосаркомой с применением различных курсов химиотерапии, а также новые подходы к лечению, включая персонализированную терапию. Отмечено, что результаты лечения детей с первичной метастатической остеосаркомой, рецидивом и рефрактерным течением заболевания остаются неудовлетворительными.

The article presents statistical data of the incidence of osteosarcoma in children, the classification of osteosarcoma, a description of the main localizations, as well as a detailed description of existing treatment protocols, including personalized therapy. Literary data are described in detail – the results of treatment of children with osteosarcoma using different courses of chemotherapy, as well as new approaches to treatment, including personalized therapy. It is noted that the results of treatment of children with primary metastatic osteosarcoma, relapse and refractory course of the disease remain unsatisfactory.

детская онкологияостеосаркомахимиотерапияперсонализированная терапиякомбинированное лечениеpediatric oncologyosteosarcomachemotherapypersonalized therapycombined treatmentReferencesПунанов Ю.А. Результаты комбинированного лечения детей и подростков с остеосаркомой / Ю.А. Пунанов, Т.В. Андреева, Г.И. Гафтон, Ю.В Гудзь, С.А. Сафонова, В.В. Набоков, В.И. Новик // Онкопедиатрия. – 2014. – № 1(2). – C. 49-53.Punanov Y.A. The Results of Combined Therapy in Children and Adolescents with Osteosarcoma / Y.A. Punanov, T.V. Andreeva, G.I. Gafton, Y.V. Gudz, S.A. Safonova, V.V. Nabokov, V.I. Novik // Oncopediatrics. – 2014. – №1(2). – C. 49-53.Avella M. Adjuvant chemotherapy with six drugs (Adriamycin, methotrexate, cisplatinum, bleomycin, cyclophosphamide and dactinomycin) for non-metastatic high grade osteosarcoma of the extremities. Results of 32 patients and comparison to 127 patients concomitantly treated with the same drugs in a neoadjuvant form / M. Avella, G. Bacci, D.J. McDonald // Chemioterapia. – 1988. – №7(2). – P. – 133-137.Avella M. Adjuvant chemotherapy with six drugs (Adriamycin, methotrexate, cisplatinum, bleomycin, cyclophosphamide and dactinomycin) for non-metastatic high grade osteosarcoma of the extremities. Results of 32 patients and comparison to 127 patients concomitantly treated with the same drugs in a neoadjuvant form / M. Avella, G. Bacci, D.J. McDonald // Chemioterapia. – 1988. – №7(2). – P. – 133-137.Bacci G. Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report / G. Bacci, S. Ferrari, F. Bertoni // Journal of clinical oncology. – 2000. – №18(24). – P.4016-4027. doi: 10.1200/JCO.2000.18.24.4016.Bacci G. Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report / G. Bacci, S. Ferrari, F. Bertoni // Journal of clinical oncology. – 2000. – №18(24). – P.4016-4027. doi: 10.1200/JCO.2000.18.24.4016.Boye K. High-Dose Chemotherapy with Stem Cell Rescue in the Primary Treatment of Metastatic and Pelvic Osteosarcoma: Final Results of the ISG/SSG II Study / K. Boye, A.B. Del Prever, E. Eiksson // Pediatric blood cancer. – 2014. – №61(5). – P. 840-845. doi: 10.1002/pbc.24868.Boye K. High-Dose Chemotherapy with Stem Cell Rescue in the Primary Treatment of Metastatic and Pelvic Osteosarcoma: Final Results of the ISG/SSG II Study / K. Boye, A.B. Del Prever, E. Eiksson // Pediatric blood cancer. – 2014. – №61(5). – P. 840-845. doi: 10.1002/pbc.24868.Cui Q. Relationship between hypermetylated MGMT gene and osteosarcoma necrosis rate after chemotherapy / Q. Cui, W. Jiang, J. Guo // Pathology oncology research. – 2011. – №17. – P. 587-591. doi: 10.1007/s12253-010-9354-7.Cui Q. Relationship between hypermetylated MGMT gene and osteosarcoma necrosis rate after chemotherapy / Q. Cui, W. Jiang, J. Guo // Pathology oncology research. – 2011. – №17. – P. 587-591. doi: 10.1007/s12253-010-9354-7.Daw N.C. Metastatic Osteosarcoma. Results of Two Consecutive Therapeutic Trials at St. Jude Children’s Research Hospital / N.C. Daw, C.A. Billups, C. Rodriques-Galindo // Cancer. – 2006. – №106. – P. 403–412. doi: 10.1002/cncr.21626.Daw N.C. Metastatic Osteosarcoma. Results of Two Consecutive Therapeutic Trials at St. Jude Children’s Research Hospital / N.C. Daw, C.A. Billups, C. Rodriques-Galindo // Cancer. – 2006. – №106. – P. 403–412. doi: 10.1002/cncr.21626.Daw N.C. Frontline Treatment of Localized Osteosarcoma Without Methotrexate: results of the St. Jude Children’s research hospital OS99 trial / N.C. Daw, M.D. Neel, B.N. Rao // Cancer. – 2011. – №117(12). – P. 2770–2778. doi: 10.1002/cncr.25715.Daw N.C. Frontline Treatment of Localized Osteosarcoma Without Methotrexate: results of the St. Jude Children’s research hospital OS99 trial / N.C. Daw, M.D. Neel, B.N. Rao // Cancer. – 2011. – №117(12). – P. 2770–2778. doi: 10.1002/cncr.25715.Ebb D. Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children’s Oncology Group / D. Ebb, G. Holcombe, M. Karen // Journal of clinical oncology. – 2012. – №30(20). – P. 2245-2551. doi: 10.1200/JCO.2011.37.4546.Ebb D. Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children’s Oncology Group / D. Ebb, G. Holcombe, M. Karen // Journal of clinical oncology. – 2012. – №30(20). – P. 2245-2551. doi: 10.1200/JCO.2011.37.4546.Ferrari S. Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1 / S. Ferrari, P. Ruqqieri, G. Cefalo // Journal of clinical oncology. – 2012. – №30(17). – P. 2112-2118. doi: 10.1200/JCO.2011.38.4420.Ferrari S. Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1 / S. Ferrari, P. Ruqqieri, G. Cefalo // Journal of clinical oncology. – 2012. – №30(17). – P. 2112-2118. doi: 10.1200/JCO.2011.38.4420.Ferrari S. Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups / S. Ferrari, S. Smeland, M. Mercuri // Journal of clinical oncology. – 2005. – №23(34). – P. 8845-8852. doi: 10.1200/JCO.2004.00.5785.Ferrari S. Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups / S. Ferrari, S. Smeland, M. Mercuri // Journal of clinical oncology. – 2005. – №23(34). – P. 8845-8852. doi: 10.1200/JCO.2004.00.5785.Fletcher, C.D.M. Pathology and Genetics of Tumours of Soft Tissue and Bone / C.D.M. Fletcher, J.A. Bridge, J.A. Hogendoorn // WHO classification 2013. – http://sarcomahelp.org/reviews/who-classification-sarcomas.htmlFletcher, C.D.M. Pathology and Genetics of Tumours of Soft Tissue and Bone / C.D.M. Fletcher, J.A. Bridge, J.A. Hogendoorn // WHO classification 2013. – http://sarcomahelp.org/reviews/who-classification-sarcomas.htmlGoorin A.M. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial / A.M. Goorin, M.B. Harris, M. Bernstein // Journal of clinical oncology. – 2002. – №2. – P. 426-433. doi: 10.1200/JCO.2002.20.2.426.Goorin A.M. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial / A.M. Goorin, M.B. Harris, M. Bernstein // Journal of clinical oncology. – 2002. – №2. – P. 426-433. doi: 10.1200/JCO.2002.20.2.426.Goorin A.M. Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651 / A.M. Goorin, D.J. Shwartzentruber, M. Devidas // Journal of clinical oncology. – 2003. – №21. – P. 1574-1580. doi: 10.1200/JCO.2003.08.165.Goorin A.M. Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651 / A.M. Goorin, D.J. Shwartzentruber, M. Devidas // Journal of clinical oncology. – 2003. – №21. – P. 1574-1580. doi: 10.1200/JCO.2003.08.165.Gorlick R. Expression of HER2/erbB-2 Correlates With Survival in Osteosarcoma / R. Gorlick, A.G. Huvos, G. Heller // Journal of clinical oncology. – 1999. – №17. – P. 2781-2788. doi: 10.1200/JCO.1999.17.9.2781.Gorlick R. Expression of HER2/erbB-2 Correlates With Survival in Osteosarcoma / R. Gorlick, A.G. Huvos, G. Heller // Journal of clinical oncology. – 1999. – №17. – P. 2781-2788. doi: 10.1200/JCO.1999.17.9.2781.Gorlick S. HER-2 Expression is Not Prognostic in Osteosarcoma; A Children’s Oncology Group Prospective Biology Study / S. Gorlick, D.A. Barkauskas, M. Krailo // Pediatric blood cancer. – 2014. – №61. – P. 1558-1564. doi: 10.1002/pbc.25074.Gorlick S. HER-2 Expression is Not Prognostic in Osteosarcoma; A Children’s Oncology Group Prospective Biology Study / S. Gorlick, D.A. Barkauskas, M. Krailo // Pediatric blood cancer. – 2014. – №61. – P. 1558-1564. doi: 10.1002/pbc.25074.Han G. C-MYC overexpression promotes osteosarcoma cell invasion via activation of MEK-ERK pathway / G. Han, Y. Wang, W. Bi // Oncology research. – 2012. – №20. – P. 149-156. doi: 10.3727/096504012X13522227232237.Han G. C-MYC overexpression promotes osteosarcoma cell invasion via activation of MEK-ERK pathway / G. Han, Y. Wang, W. Bi // Oncology research. – 2012. – №20. – P. 149-156. doi: 10.3727/096504012X13522227232237.Hattinger C.M. ERCC1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy / C.M. Hattinger, F. Michelacci, F. Sella // Histopathology. – 2015. – №67(3). – P. 338-347. doi: 10.1111/his.12653.Hattinger C.M. ERCC1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy / C.M. Hattinger, F. Michelacci, F. Sella // Histopathology. – 2015. – №67(3). – P. 338-347. doi: 10.1111/his.12653.Hegyi M. Good Prognosis of Localized Osteosarcoma in Young Patients Treated With Limb-Salvage Surgery and Chemotherapy / M. Hegyi, A.F. Semsei, Z. Jakab // Pediatric Blood Cancer. – 2011. – №57. – P. 415–422. doi: 10.1002/pbc.23172.Hegyi M. Good Prognosis of Localized Osteosarcoma in Young Patients Treated With Limb-Salvage Surgery and Chemotherapy / M. Hegyi, A.F. Semsei, Z. Jakab // Pediatric Blood Cancer. – 2011. – №57. – P. 415–422. doi: 10.1002/pbc.23172.Hinds P.S. Aggressive treatment of nonmetastatic osteosarcoma improves health-related quality of life in children and adolescents / P.S. Hinds, J.S. Gattuso, C.A. Billups // European journal of cancer. – 2009. – №45. – P. 2007-2014. doi: 10.1016/j.ejca.2009.04.020.Hinds P.S. Aggressive treatment of nonmetastatic osteosarcoma improves health-related quality of life in children and adolescents / P.S. Hinds, J.S. Gattuso, C.A. Billups // European journal of cancer. – 2009. – №45. – P. 2007-2014. doi: 10.1016/j.ejca.2009.04.020.Isakoff M.S. Poor Survival for Osteosarcoma of the Pelvis: A Report from the Children’s Oncology Group / M.S. Isakoff, D.A. Barkauskas, D. Ebb // Clinical Orthopedics Related Research. – 2012. – №470. – P. 2007–2013. doi: 10.1007/s11999-012-2284-9.Isakoff M.S. Poor Survival for Osteosarcoma of the Pelvis: A Report from the Children’s Oncology Group / M.S. Isakoff, D.A. Barkauskas, D. Ebb // Clinical Orthopedics Related Research. – 2012. – №470. – P. 2007–2013. doi: 10.1007/s11999-012-2284-9.Isakoff M.S. Osteosarcoma: current treatment and a collaborative pathway to success / M.S. Isakoff, S.S. Bielack, P. Meltzer // Journal of clinical oncology. – 2015. – №33(27) – P. 3029-3035. doi: 10.1200/JCO.2014.59.4895.Isakoff M.S. Osteosarcoma: current treatment and a collaborative pathway to success / M.S. Isakoff, S.S. Bielack, P. Meltzer // Journal of clinical oncology. – 2015. – №33(27) – P. 3029-3035. doi: 10.1200/JCO.2014.59.4895.Iwamoto Y. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO95J / Y. Iwamoto, K. Tanaka, K. Isu // Journal of orthopedic science. – 2009. – №14. – P. 397–404. doi: 10.1007/s00776-009-1347-6.Iwamoto Y. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO95J / Y. Iwamoto, K. Tanaka, K. Isu // Journal of orthopedic science. – 2009. – №14. – P. 397–404. doi: 10.1007/s00776-009-1347-6.Le Deley M.C. SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients / M.C. Le Deley, J.M. Guinebretiere, V.C. Gentet // European journal of cancer. – 2007. – №43. – P.752-761. doi: 10.1016/j.ejca.2006.10.023.Le Deley M.C. SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients / M.C. Le Deley, J.M. Guinebretiere, V.C. Gentet // European journal of cancer. – 2007. – №43. – P.752-761. doi: 10.1016/j.ejca.2006.10.023.Li J.I. CD133 expression in osteosarcoma and derivation of CD133 cells / J.I. Li, X.Y. Zhong, Z.Y. Li // Molecular medicine reports. – 2013. – №7. – P. 577-584. doi: 10.3892/mmr.2012.1231.Li J.I. CD133 expression in osteosarcoma and derivation of CD133 cells / J.I. Li, X.Y. Zhong, Z.Y. Li // Molecular medicine reports. – 2013. – №7. – P. 577-584. doi: 10.3892/mmr.2012.1231.Marina N.M. Comparison of MAPIE versus MAP in patients with poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS1): an open-label, international, randomized controlled trial / N.M. Marina, S. Smeland, S.S. Bielack // Lancet oncology. – 2016. – №17(10). – P. 1396-1408. doi: 10.1016/S1470-2045(16)30214-5.Marina N.M. Comparison of MAPIE versus MAP in patients with poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS1): an open-label, international, randomized controlled trial / N.M. Marina, S. Smeland, S.S. Bielack // Lancet oncology. – 2016. – №17(10). – P. 1396-1408. doi: 10.1016/S1470-2045(16)30214-5.Meyers P.A. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma / P.A. Meyers, J.H. Healeya, A.J. Choua // Cancer. – 2011. – №117(8). – P. 1736–1744. doi: 10.1002/cncr.25744.Meyers P.A. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma / P.A. Meyers, J.H. Healeya, A.J. Choua // Cancer. – 2011. – №117(8). – P. 1736–1744. doi: 10.1002/cncr.25744.Meyers P.A. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children’s Oncology Group / P.A. Meyers, C.L. Schwartz, M.D. Krailo // Journal of clinical oncology. – 2008. – №28(9). – P. 633-638. doi: 10.1200/JCO.2008.14.0095.Meyers P.A. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children’s Oncology Group / P.A. Meyers, C.L. Schwartz, M.D. Krailo // Journal of clinical oncology. – 2008. – №28(9). – P. 633-638. doi: 10.1200/JCO.2008.14.0095.Nguyen A. Role of topoisomerases in pediatric high grade osteosarcomas: TOP2A gene is one of the unique molecular biomarkers of chemoresponse / A. Nguyen, C. Lasthaus, E. Guerin // Cancer. – 2013. – №5. – P. 662-675. doi: 10.3390/cancers5020662.Nguyen A. Role of topoisomerases in pediatric high grade osteosarcomas: TOP2A gene is one of the unique molecular biomarkers of chemoresponse / A. Nguyen, C. Lasthaus, E. Guerin // Cancer. – 2013. – №5. – P. 662-675. doi: 10.3390/cancers5020662.Petrilli S. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: Prognostic Factors and Impact on Survival / S. Petrilli, B. de Camargo, V.O. Filho // Journal of clinical oncology. – 2006. – №24(7). – P. 1161-1168. doi: 10.1200/JCO.2005.03.5352.Petrilli S. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: Prognostic Factors and Impact on Survival / S. Petrilli, B. de Camargo, V.O. Filho // Journal of clinical oncology. – 2006. – №24(7). – P. 1161-1168. doi: 10.1200/JCO.2005.03.5352.Pitano-Garcia A. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression / A. Pitano-Garcia, M. Zalacain, L. Marrodan // Journal of pediatrics. – 2009. – №154(5). – P. 688-693. doi: 10.1016/j.jpeds.2008.Pitano-Garcia A. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression / A. Pitano-Garcia, M. Zalacain, L. Marrodan // Journal of pediatrics. – 2009. – №154(5). – P. 688-693. doi: 10.1016/j.jpeds.2008.Smeland S. Event-free survival and overall survival in 2,253 patients with osteosarcoma registered to EURAMOS-1 / S. Smeland, J.S. Whelan, S.S. Bielack // Journal of clinical oncology. – 2015. – №33. – P. 1051.Smeland S. Event-free survival and overall survival in 2,253 patients with osteosarcoma registered to EURAMOS-1 / S. Smeland, J.S. Whelan, S.S. Bielack // Journal of clinical oncology. – 2015. – №33. – P. 1051.Smeland S. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma / S. Smeland, O.S. Bruland, L. Hjorth // Acta Orthopaedica. – 2011. – №82(2). – P.211–216. doi: 10.3109/17453674.2011.566141.Smeland S. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma / S. Smeland, O.S. Bruland, L. Hjorth // Acta Orthopaedica. – 2011. – №82(2). – P.211–216. doi: 10.3109/17453674.2011.566141.Souhami R.L. Randomised trial of two regimens of chemotherapy inoperable osteosarcoma: a study of the European Osteosarcoma Intergroup / R.L. Souhami, A.W. Craft, J.W.V. der Eijken // The Lancet. – 1997. – №350. – P. 911-917. doi: 10.1016/S0140-6736(97)02307-6.Souhami R.L. Randomised trial of two regimens of chemotherapy inoperable osteosarcoma: a study of the European Osteosarcoma Intergroup / R.L. Souhami, A.W. Craft, J.W.V. der Eijken // The Lancet. – 1997. – №350. – P. 911-917. doi: 10.1016/S0140-6736(97)02307-6.Tu B. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3 / B. Tu, J. Zhu, S. Liu // Oncotarget. – 2016. – №7(30). – P. 48296-48308. doi: 10.18632/oncotarget.10219.Tu B. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3 / B. Tu, J. Zhu, S. Liu // Oncotarget. – 2016. – №7(30). – P. 48296-48308. doi: 10.18632/oncotarget.10219.Xiao X. Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma / X. Xiao, W. Wang, H. Zhang // Tumour biology. – 2015. – №36(4). – P. 2437-35. doi: 10.1007/s13277-014-2853-5.Xiao X. Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma / X. Xiao, W. Wang, H. Zhang // Tumour biology. – 2015. – №36(4). – P. 2437-35. doi: 10.1007/s13277-014-2853-5.

The authors declare that there are no conflicts of interest present.